Spots Global Cancer Trial Database for Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Official Title: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Study ID: NCT03777410

Conditions

Multiple Myeloma in Relapse

Interventions

Study Description

Brief Summary: This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen. The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.

Detailed Description: